Jones T D, Phillips W J, Smith B J, Bamford C A, Nayee P D, Baglin T P, Gaston J S H, Baker M P
Biovation Ltd, Babraham, Cambridge, UK.
J Thromb Haemost. 2005 May;3(5):991-1000. doi: 10.1111/j.1538-7836.2005.01309.x.
The development of inhibitors in hemophiliacs is a severe complication of factor VIII (FVIII) replacement therapy and is a process driven by FVIII specific T helper cells.
To finely map T cell epitopes within the whole FVIII protein in order to investigate the possibility of engineering FVIII variants with reduced propensity for inhibitor development.
T cell lines were generated from five patients with severe hemophilia who had developed inhibitors, and were screened for T cell proliferation against pools of overlapping peptides spanning the entire B domain deleted (BDD) FVIII sequence. Positive peptide pools were decoded by screening individual peptides against the T cell lines. Positive peptides, and mutants thereof, were tested for their ability to bind major histocompatibility complex (MHC) Class II and stimulate T cell proliferation in a panel of healthy donors. The activities of the corresponding mutant proteins were assessed via chromogenic assay.
One peptide, spanning FVIII amino acids 2098-2112, elicited a vigorous response from one hemophiliac donor, induced strong T cell responses in the panel of healthy donors and bound to a number of HLA-DR alleles. Mutations were made in this peptide that removed its ability to stimulate T cells of healthy donors and to bind to MHC Class II while retaining full activity when incorporated into a mutant BDD-FVIII protein.
Fine T cell epitope mapping of the entire FVIII protein is feasible, although challenging, and this knowledge may be used to create FVIII variants which potentially have reduced immunogenicity.
血友病患者体内产生抑制剂是因子VIII(FVIII)替代疗法的一种严重并发症,是由FVIII特异性辅助性T细胞驱动的过程。
精细定位整个FVIII蛋白内的T细胞表位,以研究构建抑制剂产生倾向降低的FVIII变体的可能性。
从5例已产生抑制剂的重度血友病患者中建立T细胞系,针对跨越整个B结构域缺失(BDD)FVIII序列的重叠肽池筛选T细胞增殖情况。通过针对T细胞系筛选单个肽对阳性肽池进行解码。对阳性肽及其突变体进行测试,以评估它们结合主要组织相容性复合体(MHC)II类分子的能力以及在一组健康供体中刺激T细胞增殖的能力。通过显色测定评估相应突变蛋白的活性。
一条跨越FVIII氨基酸2098 - 2112的肽在一名血友病供体中引发了强烈反应,在一组健康供体中诱导了强烈的T细胞反应,并与多个HLA - DR等位基因结合。对该肽进行突变,使其失去刺激健康供体T细胞的能力以及与MHC II类分子结合的能力,同时当整合到突变的BDD - FVIII蛋白中时保留全部活性。
对整个FVIII蛋白进行精细的T细胞表位定位是可行的,尽管具有挑战性,并且这一知识可用于创建潜在免疫原性降低的FVIII变体。